JP2011503194A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503194A5
JP2011503194A5 JP2010534154A JP2010534154A JP2011503194A5 JP 2011503194 A5 JP2011503194 A5 JP 2011503194A5 JP 2010534154 A JP2010534154 A JP 2010534154A JP 2010534154 A JP2010534154 A JP 2010534154A JP 2011503194 A5 JP2011503194 A5 JP 2011503194A5
Authority
JP
Japan
Prior art keywords
pyrazol
pyrimidin
phenylamino
ylamino
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010534154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503194A (ja
JP5480813B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/083319 external-priority patent/WO2009064835A1/en
Publication of JP2011503194A publication Critical patent/JP2011503194A/ja
Publication of JP2011503194A5 publication Critical patent/JP2011503194A5/ja
Application granted granted Critical
Publication of JP5480813B2 publication Critical patent/JP5480813B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010534154A 2007-11-16 2008-11-13 Janusキナーゼ阻害剤としての置換複素環 Expired - Fee Related JP5480813B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98860607P 2007-11-16 2007-11-16
US60/988,606 2007-11-16
PCT/US2008/083319 WO2009064835A1 (en) 2007-11-16 2008-11-13 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2011503194A JP2011503194A (ja) 2011-01-27
JP2011503194A5 true JP2011503194A5 (https=) 2012-01-05
JP5480813B2 JP5480813B2 (ja) 2014-04-23

Family

ID=40380038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010534154A Expired - Fee Related JP5480813B2 (ja) 2007-11-16 2008-11-13 Janusキナーゼ阻害剤としての置換複素環

Country Status (20)

Country Link
US (1) US8309718B2 (https=)
EP (1) EP2220068B1 (https=)
JP (1) JP5480813B2 (https=)
KR (1) KR101580482B1 (https=)
CN (1) CN101910152B (https=)
AU (1) AU2008321046B2 (https=)
BR (1) BRPI0820544A2 (https=)
CA (1) CA2704599C (https=)
CO (1) CO6280420A2 (https=)
CR (1) CR11430A (https=)
EA (1) EA020777B1 (https=)
EC (1) ECSP10010263A (https=)
ES (1) ES2569528T3 (https=)
IL (1) IL205571A (https=)
MX (1) MX2010005300A (https=)
MY (1) MY152948A (https=)
NZ (1) NZ585139A (https=)
UA (1) UA104849C2 (https=)
WO (1) WO2009064835A1 (https=)
ZA (1) ZA201004055B (https=)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060106020A1 (en) * 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
CA2673038C (en) * 2006-12-22 2015-12-15 Incyte Corporation Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제(R)―3―(4―(7H―피롤로[2,3-d]피리미딘―4―일)―1H―피라졸―1―일)―3―사이클로펜틸프로판니트릴의 염
FR2938537B1 (fr) 2008-11-14 2012-10-26 Sanofi Aventis Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.
TWI720517B (zh) 2009-01-15 2021-03-01 美商英塞特公司 製造jak抑制劑之方法及相關中間化合物
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
SI2432472T1 (sl) 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011079231A1 (en) * 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
AU2011214254B2 (en) * 2010-02-10 2016-06-09 Genon Biotechnologies Oy Dual activity kinase domains and uses thereof
JP5858434B2 (ja) * 2010-02-18 2016-02-10 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Janusキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
ES2577829T3 (es) 2010-06-04 2016-07-19 F. Hoffmann-La Roche Ag Derivados de aminopirimidina como moduladores de la LRRK2
JP2014500254A (ja) * 2010-11-09 2014-01-09 セルゾーム リミティッド Tyk2阻害剤としてのピリジン化合物およびそのアザ類似体
NO2638031T3 (https=) 2010-11-10 2018-03-10
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
ES2547916T3 (es) 2011-02-18 2015-10-09 Novartis Pharma Ag Terapia de combinación de inhibidores de mTOR/JAK
EP2702055A1 (en) * 2011-04-11 2014-03-05 Nerviano Medical Sciences S.r.l. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CA2849168A1 (en) * 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
CN103102359B (zh) * 2011-11-15 2016-11-09 江苏先声药业有限公司 嘧啶类化合物及其应用
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はahi1の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
US8809359B2 (en) * 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
EP2911675A4 (en) * 2012-10-23 2016-06-01 Merck Sharp & Dohme 2-PYRIDYLOXY-3-SUBSTITUTED 4-NITRIL-OREXINE RECEPTOR ANTAGONISTS
TWI646099B (zh) 2012-11-01 2019-01-01 英塞特控股公司 作爲jak抑制劑之三環稠合噻吩衍生物
EP2914253B1 (en) 2012-11-05 2018-01-03 NantBioScience, Inc. Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
WO2014075318A1 (zh) * 2012-11-19 2014-05-22 江苏先声药业有限公司 嘧啶类化合物及其应用
NZ746607A (en) 2012-11-21 2019-11-29 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
WO2014146249A1 (en) * 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
HUE033587T2 (hu) 2013-05-17 2017-12-28 Incyte Corp Bipirazol-származékok mint JAK inhibitorok
WO2014196793A1 (en) * 2013-06-05 2014-12-11 C&C Research Laboratories Heterocyclic derivatives and use thereof
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
EA034866B1 (ru) 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
CN105980381A (zh) 2013-11-08 2016-09-28 拜耳医药股份有限公司 取代的尿嘧啶及其用途
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
HRP20210319T1 (hr) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije inhibitora fgfr i inhibitora igf1r
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MA39987A (fr) 2014-04-30 2017-03-08 Incyte Corp Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2016105525A2 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Novel pyrimidines as egfr inhibitors and methods of treating disorders
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN107531678B (zh) * 2015-07-24 2020-12-22 上海海雁医药科技有限公司 Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用
EP3353164B1 (en) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
US11155555B2 (en) 2015-09-23 2021-10-26 Janssen Pharmaceutica Nv Compounds
US10793542B2 (en) 2016-11-22 2020-10-06 Development Center For Biotechnology Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof
KR102717072B1 (ko) 2017-10-18 2024-10-15 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
KR102925957B1 (ko) 2018-02-16 2026-02-11 인사이트 코포레이션 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
MA52655A (fr) 2018-03-30 2021-02-17 Incyte Corp Biomarqueurs pour maladie cutanée inflammatoire
CA3097025A1 (en) 2018-04-13 2019-10-17 Incyte Corporation Biomarkers for graft-versus-host disease
EP3836932A2 (en) 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Method for treating pancreatic cancer
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
CN113226321B (zh) * 2018-10-26 2024-12-17 阿利安制药有限责任公司 吡唑基化合物及其使用方法
CA3117969A1 (en) 2018-10-31 2020-05-07 Incyte Corporation Combination therapy for treatment of hematological diseases
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
CA3137152A1 (en) 2019-04-18 2020-10-22 The Johns Hopkins University Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN112142731B (zh) * 2019-06-28 2022-07-22 成都赜灵生物医药科技有限公司 一种2,4-二取代嘧啶衍生物及其制备方法和用途
WO2020259683A1 (zh) * 2019-06-28 2020-12-30 成都赜灵生物医药科技有限公司 2,4-二取代嘧啶衍生物及其制备方法和用途
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
WO2021072098A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
EP4041204A1 (en) 2019-10-10 2022-08-17 Incyte Corporation Biomarkers for graft-versus-host disease
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
JP7717065B2 (ja) 2019-11-22 2025-08-01 インサイト コーポレーション Alk2阻害剤及びjak2阻害剤を含む併用療法
AU2021243887A1 (en) * 2020-03-23 2022-11-03 Korea Research Institute Of Chemical Technology Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
MX2022015221A (es) 2020-06-02 2023-03-08 Incyte Corp Procesos para preparar un inhibidor de cinasa jano 1 (jak1).
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
IL300557A (en) 2020-08-18 2023-04-01 Incyte Corp Process and intermediates for preparing a JAK1 inhibitor
PE20231743A1 (es) 2020-08-18 2023-10-31 Incyte Corp Proceso e intermediarios para preparar un inhibidor de jak
CN114181199B (zh) * 2020-09-15 2023-09-26 成都赜灵生物医药科技有限公司 2,4-二取代嘧啶衍生物及其制备方法和用途
CN112142675B (zh) * 2020-10-09 2021-11-30 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途
CN112159394B (zh) 2020-10-09 2021-10-22 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途
AU2021362678A1 (en) 2020-10-13 2023-05-04 The Johns Hopkins University SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF
CA3204374A1 (en) 2020-12-08 2022-06-16 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
WO2022166916A1 (zh) * 2021-02-05 2022-08-11 深圳市塔吉瑞生物医药有限公司 取代的杂芳基衍生物及其组合物及用途
UA129643C2 (uk) 2021-05-03 2025-06-18 Інсайт Корпорейшн Інгібітори шляху jak1 для лікування вузлуватого свербця
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US12071439B2 (en) 2021-07-12 2024-08-27 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
AU2022361055A1 (en) * 2021-10-06 2024-04-04 Alcon Inc. Janus kinase inhibiting pyrazole compounds and uses thereof
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CA3263043A1 (en) * 2022-08-22 2024-02-29 Hangzhou Highlightll Pharmaceutical Co., Ltd JAK1/JAK2/TYK2 INHIBITORS FOR THE TOPICAL TREATMENT OF DERMATOLOGICAL DISEASES
CN115594664B (zh) * 2022-11-25 2023-02-24 英矽智能科技(上海)有限公司 一类螺环衍生物作为kif18a抑制剂

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
AU4231299A (en) 1998-06-04 1999-12-20 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
DE60037345T2 (de) 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
WO2001047922A2 (en) 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
ATE407132T1 (de) * 2000-12-05 2008-09-15 Vertex Pharma Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen
WO2002092573A2 (en) * 2001-05-16 2002-11-21 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
BR0212760A (pt) 2001-09-19 2004-12-07 Aventis Pharma Sa Compostos quìmicos
DE60213842T2 (de) 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0215844D0 (en) * 2002-07-09 2002-08-14 Novartis Ag Organic compounds
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
JP2006518381A (ja) 2003-02-07 2006-08-10 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
SE0301372D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
PT1812440E (pt) * 2004-11-04 2011-01-25 Vertex Pharma Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
JP2009513615A (ja) 2005-10-28 2009-04-02 アストラゼネカ アクチボラグ 癌の治療においてチロシンキナーゼ阻害剤として使用するための4−(3−アミノピラゾール)ピリミジン誘導体
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
CN101379060B (zh) * 2006-02-10 2012-05-23 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
WO2007105058A2 (en) 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
CA2673038C (en) 2006-12-22 2015-12-15 Incyte Corporation Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제(R)―3―(4―(7H―피롤로[2,3-d]피리미딘―4―일)―1H―피라졸―1―일)―3―사이클로펜틸프로판니트릴의 염
HUE029767T2 (en) 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
TWI720517B (zh) 2009-01-15 2021-03-01 美商英塞特公司 製造jak抑制劑之方法及相關中間化合物
SI2432472T1 (sl) 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen

Similar Documents

Publication Publication Date Title
JP2011503194A5 (https=)
KR101580482B1 (ko) 야누스 키나제 억제제로서의 4-피라졸릴-n-아릴피리미딘-2-아민 및 4-피라졸릴-n-헤테로아릴피리미딘-2-아민
HRP20231310T1 (hr) Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
JP2022531801A5 (https=)
HRP20210431T1 (hr) Pripravci tetrahidrokinolina kao inhibitori bet bromodomene
JP2011518836A5 (https=)
ES2902504T3 (es) Compuestos de indol sustituidos con piridilo
JP2015522002A5 (https=)
JP2014525448A5 (https=)
JP2019530667A5 (https=)
SI3177619T1 (en) 2- (morpholin-4-yl) -1,7-naphthyridines
ES2453474T3 (es) Derivados de aminopirazina y medicamento correspondiente
CN112638373A (zh) 细胞周期蛋白依赖性激酶抑制剂
JP2022531932A5 (https=)
JP2023503052A5 (https=)
JP2012529522A5 (https=)
JP2019519484A5 (https=)
US20100137313A1 (en) Heterocyclic derivatives and methods of use thereof
JP2007508346A5 (https=)
JP2018507235A5 (https=)
JP2014511869A5 (https=)
JP2009513575A5 (https=)
HRP20201746T1 (hr) Aromatski derivati sulfonamida
JP2008513500A5 (https=)
JP2010510319A5 (https=)